Last reviewed · How we verify
TAS-114
At a glance
| Generic name | TAS-114 |
|---|---|
| Sponsor | Taiho Oncology, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1 (PHASE2)
- A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors (PHASE1)
- A Trial of TAS-114 in Combination With S-1 (PHASE1)
- A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |